Drugs / PegIFN-2b
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01432535 | Nov 2011 → Aug 2012 | impaired renal function disease | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02089685 | Mar 2014 → Apr 2021 | melanoma, renal cell carcinoma | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT03123653 | Mar 2017 → Sep 2019 | hepatitis B virus infection | Institute of Liver and Biliary Sciences, India | Unknown | No outcome recorded |
| Comparator or background therapy3 trials | ||||||
| Phase 2 | NCT00959699 Comparator | Nov 2009 → May 2012 | HIV infectious disease, hepatitis C virus infection | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 4 | NCT01770223 Background | Jan 2014 → Dec 2015 | hepatitis C virus infection | Merck Sharp & Dohme LLC | Withdrawn | No outcome recorded |
| Phase 4 | NCT01756079 Background | Feb 2013 → Nov 2015 | chronic hepatitis C virus infection | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PegIFN-2b | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01756079 ↗ |
| Known as | Sylatron | “PegIFN-2b (Sylatron®)” NCT01432535 ↗ |
| Route | Subcutaneous | “PegIFN-2b (1.5 μg/kg/week subcutaneously)” NCT00959699 ↗ |